Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Summary

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Eligibility

Inclusion Criteria:

* Participants have initiated treatment with deucravacitinib monotherapy 4 to 8 weeks earlier according to clinical practice and to reimbursement criteria determined by National Drug Agency in Italy (AIFA)
* Patients have moderate to severe plaque psoriasis
* Patients have signed informed consent form (ICF)

Exclusion Criteria:

* Simultaneous participation in any interventional study for their moderate-to-severe psoriasis
* Inability to participate to the study for the following reasons: patients unable to understand the aim of the study, patients unable to understand and sign the ICF

Conditions2

Interventions1

Related trials

• A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis — Bristol-Myers Squibb
• Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic Disease — University of Texas Southwestern Medical Center

Browse More Trials